MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

15.38 -0.37 (-2.35%)
Streaming Delayed Price Updated: 1:52 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PureTech Health plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee
From PureTech Health plc
Via Business Wire
News headline image
PureTech Provides End of Year Report on Key Progress Across Wholly Owned Programs and Founded Entities
From PureTech Health
Via Business Wire
News headline image
PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions
From PureTech Health plc
Via Business Wire
News headline image
PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions
From PureTech Health plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Biofrontera (NASDAQ:BFRI) shares ... 
Via Benzinga
News headline image
PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Participation in Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
From PureTech Health plc
Via Business Wire
News headline image
PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Participation at the Jefferies London Healthcare Conference
From PureTech Health plc
Via Business Wire
News headline image
PureTech Is Pleased to Note Publication in Nature’s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
From PureTech Health plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Valneva (NASDAQ:VALN) stock moved upwards by 29.61% to $49.9 during Monday's regular session. Valneva's stock is trading at a volume of 143.0K shares as of... 
Via Benzinga
News headline image
Earnings Scheduled For August 24, 2021 ↗
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is likely to report earnings for its second quarter. • Genetron Holdings (NASDAQ:GTH) is... 
Via Benzinga
News headline image
PureTech Health plc – Half-Year Report
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer
From PureTech Health plc
Via Business Wire
News headline image
Imbrium Therapeutics To Develop PureTech's Non-Opioid Candidate For Chronic Bladder Condition ↗
Imbrium Therapeutics has exercised a license option to develop PureTech Health plc's (NASDAQ: PRTC) LYT-503/IMB-150 (formerly designated as ALV-107... 
Via Benzinga
News headline image
PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503/IMB-150 for Interstitial Cystitis/Bladder Pain Syndrome
From PureTech Health plc
Via Business Wire
News headline image
PureTech: Notice of Half-Yearly Results
From PureTech Health plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story